Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | LSS | P48449 | 3/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26617983 | 0.91 | KDM4E (0.57) | SIGMAR1KMT2AOPRM1KDM4EALDH1A1 | |
| SCHEMBL20871938 | 0.88 | KDM4E (0.62) | SIGMAR1KMT2AOPRM1KDM4EALDH1A1 | |
| SCHEMBL8437462 | 0.85 | SIGMAR1 (0.67) | SIGMAR1OPRM1SLC18A3GRIN2B | |
| SCHEMBL9965859 | 0.84 | NAAA (0.55) | SIGMAR1OPRM1KDM4EALDH1A1HRH3 | |
| SCHEMBL20281451 | 0.82 | KMT2A (0.53) | SIGMAR1KMT2AOPRM1HRH3HRH4 | |
| SCHEMBL29951372 | 0.82 | SIGMAR1 (0.50) | SIGMAR1KMT2AOPRM1KDM4EALDH1A1 | |
| SCHEMBL11251947 | 0.82 | HRH3 (0.67) | SIGMAR1OPRM1KDM4EALDH1A1HRH3 | |
| SCHEMBL17886958 | 0.81 | KMT2A (0.49) | SIGMAR1KMT2AOPRM1HRH3HRH4 | |
| SCHEMBL8258573 | 0.81 | KMT2A (0.49) | SIGMAR1KMT2AOPRM1HRH3HRH4 | |
| SCHEMBL8442356 | 0.81 | KDM4E (0.68) | SIGMAR1KMT2AOPRM1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | SIGMAR1 1063/4885KMT2A 1797/4885OPRM1 1787/4885 |
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | SIGMAR1 344/4885KMT2A 3318/4885OPRM1 711/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | SIGMAR1 391/4885KMT2A 2232/4885OPRM1 1101/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | SIGMAR1 1063/4885KMT2A 1797/4885OPRM1 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.